NADK2: A Potential Drug Target for Cancer and Neurodegenerative Disorders

Target Name: NADK2

NCBI ID: G133686

NADK2

NADK2: A Potential Drug Target for Cancer and Neurodegenerative Disorders

NADK2 (nicotinamide adenine dinucleotide-dependent cyclic ADP-ribose synthase) is an enzyme that plays a crucial role in the metabolism of DNA, RNA, and protein in the human body. It is a key player in the DNA damage response, which is a critical pathway that helps the cell repair itself when it experiences damage to its DNA. NADK2 is also involved in the production of adenosine, a well-known signaling molecule that plays a variety of roles in the body, including regulating inflammation and immune responses.

Recent studies have suggested that NADK2 may have potential as a drug target or biomarker for a variety of diseases. One potential mechanism by which NADK2 could be targeted is through its role in the production of adenosine. High levels of adenosine have been linked to a number of diseases, including heart failure, cancer, and neurodegenerative disorders. By inhibiting the activity of NADK2, researchers may be able to reduce the production of adenosine and potentially improve the health outcomes associated with these conditions.

Another potential mechanism by which NADK2 could be targeted is through its role in the DNA damage response. DNA damage can occur due to a variety of factors, including exposure to radiation, chemicals, or environmental factors. The DNA damage response is a critical pathway that helps the cell repair itself when it experiences damage to its DNA. NADK2 is involved in this process, and research has suggested that it may play a key role in the regulation of the DNA damage response. By targeting NADK2, researchers may be able to improve the ability of the body to repair itself from DNA damage, which could be a potential therapeutic approach for a variety of diseases.

In addition to its potential as a drug target or biomarker, NADK2 has also been shown to have potential as a therapeutic approach for a variety of diseases. For example, some studies have suggested that NADK2 may have potential as a treatment for cancer, particularly for cancers that are sensitive to DNA damage, such as breast cancer and colon cancer. This is because high levels of adenosine have been linked to the development and progression of many types of cancer. By inhibiting the production of adenosine, NADK2 may be able to reduce the risk of cancer progression and improve the overall health outcomes associated with this disease.

Another potential application of NADK2 as a therapeutic approach is its role in the treatment of neurodegenerative disorders. Neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, are characterized by the progressive loss of brain cells and can have a variety of negative impacts on an individual's quality of life. Some studies have suggested that NADK2 may play a key role in the development and progression of these disorders, and that targeting NADK2 may be a potential therapeutic approach. By reducing the production of adenosine, NADK2 may be able to improve the ability of the brain to repair itself from damage and potentially slow the progression of neurodegenerative disorders.

In conclusion, NADK2 is a complex enzyme that plays a crucial role in the metabolism of DNA, RNA, and protein in the human body. recent studies have suggested that NADK2 may have potential as a drug target or biomarker for a variety of diseases, including cancer, neurodegenerative disorders, and heart failure. By inhibiting the activity of NADK2, researchers may be able to improve the health outcomes associated with these conditions. Further research is needed to fully understand the potential therapeutic applications of NADK2.

Protein Name: NAD Kinase 2, Mitochondrial

Functions: Mitochondrial NAD(+) kinase that phosphorylates NAD(+) to yield NADP(+). Can use both ATP or inorganic polyphosphate as the phosphoryl donor. Also has weak NADH kinase activity in vitro; however NADH kinase activity is much weaker than the NAD(+) kinase activity and may not be relevant in vivo

The "NADK2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NADK2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets